The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s demonstrating significant potential in clinical trials for managing obesity. Unlike some existing weight loss treatments, retatrutide appears to provide a greater substant